PE20231681A1 - Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos - Google Patents
Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usosInfo
- Publication number
- PE20231681A1 PE20231681A1 PE2023002389A PE2023002389A PE20231681A1 PE 20231681 A1 PE20231681 A1 PE 20231681A1 PE 2023002389 A PE2023002389 A PE 2023002389A PE 2023002389 A PE2023002389 A PE 2023002389A PE 20231681 A1 PE20231681 A1 PE 20231681A1
- Authority
- PE
- Peru
- Prior art keywords
- tl1a
- compositions
- ligands
- antibodies against
- humanized antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150825P | 2021-02-18 | 2021-02-18 | |
| US202163180892P | 2021-04-28 | 2021-04-28 | |
| US202163226037P | 2021-07-27 | 2021-07-27 | |
| US202163285781P | 2021-12-03 | 2021-12-03 | |
| PCT/US2022/016841 WO2022178159A1 (en) | 2021-02-18 | 2022-02-17 | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231681A1 true PE20231681A1 (es) | 2023-10-19 |
Family
ID=82931032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002389A PE20231681A1 (es) | 2021-02-18 | 2022-02-17 | Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240309104A1 (https=) |
| EP (1) | EP4294444A4 (https=) |
| JP (1) | JP2024506940A (https=) |
| KR (1) | KR20230157973A (https=) |
| AU (1) | AU2022223420A1 (https=) |
| BR (1) | BR112023016672A2 (https=) |
| CA (1) | CA3207817A1 (https=) |
| CL (1) | CL2023002424A1 (https=) |
| CO (1) | CO2023011969A2 (https=) |
| CR (1) | CR20230436A (https=) |
| DO (1) | DOP2023000162A (https=) |
| EC (1) | ECSP23070237A (https=) |
| GE (2) | GEAP202416596A (https=) |
| IL (1) | IL305312A (https=) |
| JO (1) | JOP20230185A1 (https=) |
| MX (1) | MX2023009622A (https=) |
| PE (1) | PE20231681A1 (https=) |
| TW (1) | TW202246322A (https=) |
| WO (1) | WO2022178159A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| AU2020275413A1 (en) | 2019-05-14 | 2021-12-23 | Cedars-Sinai Medical Center | TL1A patient selection methods, systems, and devices |
| NZ787680A (en) | 2019-10-24 | 2026-02-27 | Cedars Sinai Medical Center | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| WO2024137353A1 (en) * | 2022-12-22 | 2024-06-27 | Prometheus Biosciences, Inc. | Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors |
| WO2024173838A2 (en) * | 2023-02-17 | 2024-08-22 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the bile duct |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| US20250109209A1 (en) | 2023-10-03 | 2025-04-03 | Absci Corporation | Tl1a associated antibody compositions and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9683998B2 (en) * | 2013-11-13 | 2017-06-20 | Pfizer Inc. | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof |
| MX392069B (es) * | 2016-05-09 | 2025-03-21 | Bristol Myers Squibb Co | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. |
| KR20190082815A (ko) * | 2016-10-26 | 2019-07-10 | 세다르스-신나이 메디칼 센터 | 중화 항-tl1a 단일 클론 항체 |
| CN112585165B8 (zh) * | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| TW202600603A (zh) * | 2019-10-24 | 2026-01-01 | 美商普羅米修斯生物科學股份有限公司 | 針對類-tnf配體1a (tl1a)之人類化抗體及其用途 |
-
2022
- 2022-02-17 TW TW111105898A patent/TW202246322A/zh unknown
- 2022-02-17 BR BR112023016672A patent/BR112023016672A2/pt unknown
- 2022-02-17 GE GEAP202416596A patent/GEAP202416596A/en unknown
- 2022-02-17 CA CA3207817A patent/CA3207817A1/en active Pending
- 2022-02-17 AU AU2022223420A patent/AU2022223420A1/en active Pending
- 2022-02-17 JP JP2023549820A patent/JP2024506940A/ja active Pending
- 2022-02-17 IL IL305312A patent/IL305312A/en unknown
- 2022-02-17 WO PCT/US2022/016841 patent/WO2022178159A1/en not_active Ceased
- 2022-02-17 KR KR1020237031689A patent/KR20230157973A/ko active Pending
- 2022-02-17 EP EP22756949.8A patent/EP4294444A4/en active Pending
- 2022-02-17 GE GEAP202316354A patent/GEAP202316354A/en unknown
- 2022-02-17 MX MX2023009622A patent/MX2023009622A/es unknown
- 2022-02-17 PE PE2023002389A patent/PE20231681A1/es unknown
- 2022-02-17 CR CR20230436A patent/CR20230436A/es unknown
- 2022-02-17 US US18/546,938 patent/US20240309104A1/en active Pending
-
2023
- 2023-08-09 JO JOJO/P/2023/0185A patent/JOP20230185A1/ar unknown
- 2023-08-16 CL CL2023002424A patent/CL2023002424A1/es unknown
- 2023-08-17 DO DO2023000162A patent/DOP2023000162A/es unknown
- 2023-09-08 CO CONC2023/0011969A patent/CO2023011969A2/es unknown
- 2023-09-14 EC ECSENADI202370237A patent/ECSP23070237A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023011969A2 (es) | 2023-09-29 |
| JP2024506940A (ja) | 2024-02-15 |
| GEAP202316354A (en) | 2023-12-25 |
| IL305312A (en) | 2023-10-01 |
| CA3207817A1 (en) | 2022-08-25 |
| EP4294444A4 (en) | 2025-04-16 |
| WO2022178159A1 (en) | 2022-08-25 |
| KR20230157973A (ko) | 2023-11-17 |
| DOP2023000162A (es) | 2023-10-15 |
| ECSP23070237A (es) | 2023-10-31 |
| CR20230436A (es) | 2023-11-01 |
| US20240309104A1 (en) | 2024-09-19 |
| EP4294444A1 (en) | 2023-12-27 |
| JOP20230185A1 (ar) | 2023-08-09 |
| CL2023002424A1 (es) | 2024-01-05 |
| GEAP202416596A (en) | 2024-10-28 |
| AU2022223420A1 (en) | 2023-09-21 |
| TW202246322A (zh) | 2022-12-01 |
| MX2023009622A (es) | 2023-08-28 |
| BR112023016672A2 (pt) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231681A1 (es) | Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos | |
| CL2024002330A1 (es) | Anticuerpo que se une al ligando 1a similar a factor de necrosis tumoral (tl1a). | |
| CL2020003046A1 (es) | Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018) | |
| MX2022004942A (es) | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos. | |
| CN104144948B (zh) | 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架 | |
| ES2818184T3 (es) | Anticuerpo anti-Notch 4 humano | |
| EA201100779A1 (ru) | Композиции антител к cxcr1 и способы их применения | |
| AR080794A1 (es) | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 | |
| PE20181336A1 (es) | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos | |
| AR083785A1 (es) | Anticuerpos humanos contra el ligando 1a de tipo tnf (factor de necrosis tumoral) humano (tl1a) | |
| RU2018140960A (ru) | Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4 | |
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| EA033387B1 (ru) | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 | |
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. | |
| EP3580230A1 (en) | Immune-cell targeted bispecific chimeric proteins and uses thereof | |
| JP2015526440A5 (https=) | ||
| ES2923677T3 (es) | Novedosos anticuerpos anti-GPVI humanos y usos de los mismos | |
| JP2016520520A5 (https=) | ||
| PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos | |
| PE20081553A1 (es) | Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide | |
| Szabó et al. | Antitumor activity of DLX1008, an anti-VEGFA antibody fragment with low picomolar affinity, in human glioma models | |
| PE20231082A1 (es) | Muteinas de il-10 y proteinas de fusion de las mismas referencia cruzada a solicitudes relacionadas | |
| AR124063A1 (es) | Anticuerpo biespecífico anti-tspan8 / anti-cd3 y anticuerpo anti-tspan8 | |
| CL2025000202A1 (es) | Anticuerpos anti-tl1a para el tratamiento de la colitis ulcerosa y la enfermedad de crohn | |
| AR102647A1 (es) | Respuesta de predicción a un antagonista de vegf |